Informations générales (source: ClinicalTrials.gov)
(THYMO B)
Observational
University Hospital, Brest (Voir sur ClinicalTrials)
février 2015
février 2018
29 juin 2024
The investigators expect to better characterise B cell subpopulation and functional
properties early after graft, to analyse effect of induction therapy (thymoglobulin
versus basiliximab) on B cells, and to compare this B cell profiles with those obtained
in our previous study in patients with chronic Antibody Mediated Rejection (cAMR)
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Brest - 29200 - Brest - France | Yannick LE MEUR, MD PhD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Tours University Hospital - 37000 - Tours - France | Mathias Buchler, PhD MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age >18 years old
- Recipient of a renal allograft
- Patient receiving either basiliximab or thymoglobulin as in induction therapy for
renal transplant
- Patient presenting a low immunologic risk
- Patient not opposed to his (her) study participation
- Age >18 years old
- Recipient of a renal allograft
- Patient receiving either basiliximab or thymoglobulin as in induction therapy for
renal transplant
- Patient presenting a low immunologic risk
- Patient not opposed to his (her) study participation
- Patient participating in a clinical trial